1. Home
  2. RILYP vs GALT Comparison

RILYP vs GALT Comparison

Compare RILYP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo B. Riley Financial Inc.

RILYP

B. Riley Financial Inc.

HOLD

Current Price

$13.44

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$3.42

Market Cap

297.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RILYP
GALT
Founded
1973
2000
Country
United States
United States
Employees
1380
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
297.0M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
RILYP
GALT
Price
$13.44
$3.42
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
8.8K
528.1K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
7.03%
N/A
EPS Growth
N/A
36.84
EPS
N/A
N/A
Revenue
$854,383,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$2.03
52 Week High
$17.52
$7.13

Technical Indicators

Market Signals
Indicator
RILYP
GALT
Relative Strength Index (RSI) 44.68 43.95
Support Level $12.01 $2.75
Resistance Level $14.50 $3.35
Average True Range (ATR) 0.47 0.32
MACD 0.11 -0.11
Stochastic Oscillator 68.80 28.78

Price Performance

Historical Comparison
RILYP
GALT

About RILYP B. Riley Financial Inc.

BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services, telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across various business lines. The Group has seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Capital Markets segment, which provides investment banking and institutional brokerage services, offers loans, trades in equity securities, and maintains an investment portfolio of public and private equities and debt securities. Geographically, the Group derives maximum revenue from its business in North America.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: